Assessment of TREC, KREC and telomere length in long-term survivors after allogeneic HSCT: the role of GvHD and graft source and evidence for telomere homeostasis in young recipients.

Abstract:

:Reconstitution of the adaptive immune system following allogeneic hematopoietic stem cell transplantation is crucial for beneficial outcome and is affected by several factors, such as GvHD and graft source. The impact of these factors on immune reconstitution has been thoroughly investigated during the early phase after transplantation. However, little is known about their long-term effect. Similarly, leukocyte telomere length (TL) shortening has been reported shortly after transplantation. Nevertheless, whether TL shortening continues in long-term aspect is still unsettled. Here, we assessed T-cell receptor excision circle (TREC), kappa deleting recombination excision circle (KREC) and leukocyte TL in recipients and donors several years post transplantation (median 17 years). Our analysis showed that, recipients who received bone marrow (BM) as the graft source have higher levels of both TREC and KREC. Also, chronic GvHD affected TREC levels and TL but not KREC levels. Finally, we show that recipient's TL was longer than respective donors in a group of young age recipients with high KREC levels. Our results suggest that BM can be beneficial for long-term adaptive immune recovery. We also present supporting evidence for recipient telomere homeostasis, especially in young age recipients, rather than telomere shortening.

journal_name

Bone Marrow Transplant

authors

Gaballa A,Norberg A,Stikvoort A,Mattsson J,Sundberg B,Uzunel M,Remberger M,Uhlin M

doi

10.1038/bmt.2017.216

subject

Has Abstract

pub_date

2018-01-01 00:00:00

pages

69-77

issue

1

eissn

0268-3369

issn

1476-5365

pii

bmt2017216

journal_volume

53

pub_type

杂志文章
  • 'Fetal' erythropoiesis following bone marrow transplantation as estimated by the number of F cells in the peripheral blood.

    abstract::The aim of this study was to define factor(s) influencing fetal erythropoiesis following bone marrow transplantation. Thirty-one transplanted patients (14 males, 17 females) were studied. The underlying diseases were chronic myelogenous leukaemia (CML, 18 patients), acute myeloblastic leukaemia (AML, 7 patients) and a...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Meletis J,Papavasiliou S,Yataganas X,Vavourakis S,Konstantopoulos K,Poziopoulos C,Samarkos M,Michali E,Dalekou M,Eliopoulos G

    更新日期:1994-11-01 00:00:00

  • Quantitative molecular methods to monitor the response of CML patients to interferon-alpha.

    abstract::Interferon-alpha (IFN-alpha) induces cytogenetic responses of variable degree in patients with CML. We sought to establish the relationship between BCR-ABL transcript numbers measured by competitive two-step reverse transcription polymerase chain reaction (RT-PCR) and cytogenetic status in CML patients treated with IF...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Hochhaus A,Lin F,Reiter A,Skladny H,Hehlmann R,Goldman JM,Cross NC

    更新日期:1996-05-01 00:00:00

  • Blood tacrolimus concentrations in bone marrow transplant patients undergoing plasmapheresis.

    abstract::Microangiopathic hemolytic anemia (MAHA) is a well-described complication of stem cell transplantation. Plasmapheresis is one modality utilized as therapy for patients who develop this complication. However, plasmapheresis may alter whole blood levels of certain medications and its effect on tacrolimus in bone marrow ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702174

    authors: Hale GA,Reece DE,Munn RK,Kniska AB,Phillips GL

    更新日期:2000-02-01 00:00:00

  • Long-term survival in advanced chronic myelogenous leukemia following bone marrow transplantation from haploidentical related donors.

    abstract::From 1987 to 1991, 26 patients with CML and a median age of 31 years received allogeneic BMT from a partially mismatched related donor (PMRD) who shared at least one haplotype with the recipient. Nine patients were in accelerated phase (AP), and 11 patients were in blast crisis (BC) at the time of BMT. Patients were m...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Bishop MR,Henslee-Downey PJ,Anderson JR,Romond EH,Marciniak E,Yankey R,Reeves M,Thompson JS

    更新日期:1996-10-01 00:00:00

  • High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas.

    abstract::Peripheral T cell lymphomas (PTCL) have a poorer prognosis after conventional treatment than do high-grade B cell lymphomas. The place for high-dose therapy (HDT) with autologous stem cell support in these patients is still not clear. Forty patients, 10 women and 30 men, median age 41.5 years (range 16-61) with PTCL w...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,多中心研究

    doi:10.1038/sj.bmt.1702867

    authors: Blystad AK,Enblad G,Kvaløy S,Berglund A,Delabie J,Holte H,Carlson K,Kvalheim G,Bengtsson M,Hagberg H

    更新日期:2001-04-01 00:00:00

  • Mobilization of PBSCs with chemotherapy and recombinant human G-CSF: a randomized evaluation of early vs late administration of recombinant human G-CSF.

    abstract::The optimal timing for recombinant human (rh)G-CSF administration after chemotherapy for PBSC mobilization has not yet been determined. In this study, we compared two different time schedules of rhG-CSF; 4th (early) vs 7th day (late), in 48 consecutive patients with multiple myeloma and lymphoma undergoing PBSC mobili...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1038/bmt.2009.161

    authors: Ozcelik T,Topcuoglu P,Beksac M,Ozcan M,Arat M,Biyikli Z,Bakanay SM,Ilhan O,Gurman G,Arslan O,Demirer T

    更新日期:2009-12-01 00:00:00

  • Salivary immunoglobulins in recipients of bone marrow grafts. II. Transient secretion of donor-derived salivary IgA following transplantation of T cell-depleted bone marrow.

    abstract::Patients undergoing bone marrow transplantation (BMT) have decreased levels of salivary Ig over long periods of time. However, shortly after transplantation, a transient rise of Ig concentration in their saliva gland is detected. In order to trace the origin of this Ig, seven BM donors were immunized with tetanus toxo...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Chaushu S,Chaushu G,Garfunkel A,Slavin S,Or R,Yefenof E

    更新日期:1994-12-01 00:00:00

  • Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG.

    abstract::The application of myeloablative Allo-SCT is limited by its associated morbidity and mortality. Reduced-intensity conditioning regimens attempt to diminish these, but are associated with a higher risk of disease relapse. Given the evidence of activity of clofarabine and cytarabine in myelodysplastic syndrome/acute mye...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/bmt.2008.423

    authors: Martin MG,Uy GL,Procknow E,Stockerl-Goldstein K,Cashen A,Westervelt P,Abboud CN,Augustin K,Luo J,DiPersio JF,Vij R

    更新日期:2009-07-01 00:00:00

  • Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure.

    abstract::Numerous studies have reported the feasibility and safety of autologous SCT (ASCT) in patients with multiple myeloma (MM) and mild to moderate renal impairment, but there are limited data in dialysis-dependent patients. In this retrospective study, we reviewed the toxicities and efficacy outcomes of 33  MM patients wi...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/bmt.2014.226

    authors: St Bernard R,Chodirker L,Masih-Khan E,Jiang H,Franke N,Kukreti V,Tiedemann R,Trudel S,Reece D,Chen CI

    更新日期:2015-01-01 00:00:00

  • Evaluation of histogenesis of B-lymphocytes in pediatric EBV-related post-transplant lymphoproliferative disorders.

    abstract::Post-transplant lymphoproliferative disorders (PTLD) are morphologically/clinically heterogeneous. The main goal of this study was to define the histogenesis of PTLD (B-cell phenotype, EBV-related) in seven pediatric patients after allogeneic T-cell-depleted bone marrow transplantation. Immunohistochemical stains usin...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704395

    authors: Abed N,Casper JT,Camitta BM,Margolis D,Trost B,Orentas R,Chang CC

    更新日期:2004-02-01 00:00:00

  • Cardiac complications in patients undergoing a reduced-intensity conditioning hematopoietic stem cell transplantation.

    abstract::Reduced-intensity conditioning (RIC) extends hematopoietic stem cell transplants (HSCT) to elderly or debilitated patients who are not candidates for HSCT. The incidence and outcomes of cardiac complications have been reported following myeloablative HSCT. We assessed the incidence and outcomes of cardiac complication...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2009.97

    authors: Peres E,Levine JE,Khaled YA,Ibrahim RB,Braun TM,Krijanovski OI,Mineishi S,Abidi MH

    更新日期:2010-01-01 00:00:00

  • Open-label, single arm, multicenter phase II study of VIDL induction chemotherapy followed by upfront autologous stem cell transplantation in patients with advanced stage extranodal NK/T-cell lymphoma.

    abstract::The clinical outcome of advanced-stage Extranodal NK/T cell lymphoma (ENKTL) patients using conventional chemotherapy is extremely poor. The aim of this study was to investigate the outcomes of advanced-stage ENKTL patients treated with non-anthracycline-based chemotherapy followed by upfront autologous stem cell tran...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-01160-2

    authors: Song GY,Yoon DH,Suh C,Moon JH,Baek DW,Kim JS,Lee GW,Yi JH,Park Y,Jung KS,Kim SJ,Yang DH,Kim WS

    更新日期:2020-12-04 00:00:00

  • Autoimmune hemolytic anemia following T cell-depleted allogeneic bone marrow transplantation.

    abstract::The development of immune-mediated hemolytic anemia is a well-recognized complication after allogeneic bone marrow transplantation (BMT). The majority of reported cases, however, have been alloimmune in origin due to ABO or minor red blood cell antigen incompatibilities between the donor and recipient. In this study, ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Drobyski WR,Potluri J,Sauer D,Gottschall JL

    更新日期:1996-06-01 00:00:00

  • A prospective study of Epstein-Barr virus load in 85 hematopoietic stem cell transplants.

    abstract::EBV viral load (EBV-VL) in PBMC was prospectively determined by semi-quantitative PCR in 85 stem cell transplants (40 genoidentical, 45 non-genoidentical) in order to characterize the kinetics of EBV-VL and to assess the ability of this measure to predict the development of EBV-induced lymphoproliferative disease (EBV...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1703331

    authors: Sirvent-Von Bueltzingsloewen A,Morand P,Buisson M,Souillet G,Chambost H,Bosson JL,Bordigoni P

    更新日期:2002-01-01 00:00:00

  • Matched unrelated or matched sibling donors result in comparable outcomes after non-myeloablative HSCT in patients with AML or MDS.

    abstract::The impact of allelic HLA matching in patients with AML and myelodysplastic syndrome (MDS) who receive allogeneic PBSC after a reduced-intensity conditioning (RIC) regimen is unclear. From January 2000 to December 2010, 108 consecutive patients with AML (n=63) and MDS (n=45) received PBSC after RIC in our center, eith...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2013.50

    authors: Robin M,Porcher R,Adès L,Boissel N,Raffoux E,Xhaard A,Larghero J,Gardin C,Himberlin C,Delmer A,Fenaux P,Dombret H,Socié G,Peffault de Latour R

    更新日期:2013-10-01 00:00:00

  • Reduced-intensity vs myeloablative conditioning allogeneic hematopoietic SCT for patients aged over 45 years with ALL in remission: a study from the Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT).

    abstract::In this study, outcomes for 575 adult ALL patients aged ≥45 years who underwent first allo-SCT in CR were analyzed according to the type of conditioning regimen (myeloablative conditioning (MAC) for 369 patients vs reduced-intensity conditioning (RIC) for 206 patients). Patients in the RIC group were older (median age...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,多中心研究

    doi:10.1038/bmt.2013.68

    authors: Tanaka J,Kanamori H,Nishiwaki S,Ohashi K,Taniguchi S,Eto T,Nakamae H,Minagawa K,Miyamura K,Sakamaki H,Morishima Y,Kato K,Suzuki R,Nishimoto N,Oba K,Masauzi N

    更新日期:2013-11-01 00:00:00

  • Predicting the severity of graft-versus-host disease from interleukin-10 levels after bone marrow transplantation.

    abstract::Acute graft-versus-host disease (GVHD) is the most important complication of allogeneic bone marrow transplantation. We investigated the possibility of predicting severe acute GVHD using plasma interleukin-10 levels in 31 patients who underwent allogeneic bone marrow transplantation. In patients with acute GVHD, the i...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702010

    authors: Takatsuka H,Takemoto Y,Okamoto T,Fujimori Y,Tamura S,Wada H,Okada M,Yamada S,Kanamaru A,Kakishita E

    更新日期:1999-11-01 00:00:00

  • A randomized trial of amifostine as a cytoprotectant for patients receiving myeloablative therapy for allogeneic hematopoietic stem cell transplantation.

    abstract::We initiated a randomized study of amifostine (the organic thiophosphate formerly known as WR-2721) given to patients during myeloablative conditioning therapy for allogeneic bone marrow transplantation. Amifostine was given at a dose of 1000 mg/day of conditioning and was well tolerated if attention was given to seru...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1038/sj.bmt.1704521

    authors: Hwang WY,Koh LP,Ng HJ,Tan PH,Chuah CT,Fook SC,Chow H,Tan KW,Wong C,Tan CH,Goh YT

    更新日期:2004-07-01 00:00:00

  • Impact of high-dose chemotherapy on antigen-specific T cell immunity in breast cancer patients. Application of new flow cytometric method.

    abstract::The present study analyses the influence of high-dose chemotherapy (HD) and autologous stem cell transplantation on natural and vaccine-induced specific immunity in breast cancer patients. Peripheral blood was collected from five breast cancer patients at serial time points in connection with treatment and in a follow...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1703521

    authors: Svane IM,Nikolajsen K,Hansen SW,Kamby C,Nielsen DL,Johnsen HE

    更新日期:2002-04-01 00:00:00

  • Efficiency of allogeneic hematopoietic SCT from HLA fully-matched non-sibling relatives: a new prospect of exploiting extended family search.

    abstract::The best donors for hematopoietic SCT (HSCT) are fully-matched siblings. In patients without fully-matched siblings, HLA registries or cord blood banks are alternative strategies with some restrictions. Owing to the high rate of consanguineous marriage in our country, between 2006 and 2013, extended family searches we...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2014.307

    authors: Hamidieh AA,Dehaghi MO,Paragomi P,Navaei S,Jalali A,Eslami GG,Behfar M,Ghavamzadeh A

    更新日期:2015-04-01 00:00:00

  • New strategies in GVHD prophylaxis.

    abstract::Despite immunosuppressive therapy using cyclosporine (CsA) and prednisolone and methotrexate (MTX), the incidence for aGVHD grade II to IV after transplantation from HLA matched unrelated donors (MUD) is 78%, the incidence for grade III and IV 36%. Since GVHD contributes to morbidity and mortality after MUD-BMT, a mor...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702346

    authors: Kiehl MG,Shipkova M,Basara N,Blau WI,Fauser AA

    更新日期:2000-05-01 00:00:00

  • Mesenchymal stem cells: heading into the clinic.

    abstract::In recent years, there has been an increasing interest in non-hematopoietic pluripotent progenitor cells that are found in the bone marrow. Mesenchymal stem cells (MSCs) are the first non-hematopoietic progenitors to be isolated from the bone marrow and extensively characterized. In addition to their ability to suppor...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/sj.bmt.1702791

    authors: Koç ON,Lazarus HM

    更新日期:2001-02-01 00:00:00

  • Donor leucocyte infusions after chemotherapy for patients relapsing with acute leukaemia following allogeneic BMT.

    abstract::Four patients with acute myeloid leukaemia relapsed within 6 months of allogeneic BMT. Three patients were treated with cytosine arabinoside and amsacrine while the fourth received no chemotherapy. All patients received infusions of leucocytes obtained by repeated leukapheresis from the original bone marrow donor. Thr...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Szer J,Grigg AP,Phillips GL,Sheridan WP

    更新日期:1993-02-01 00:00:00

  • The role of high-dose chemotherapy with autologous bone marrow transplantation in the treatment of breast cancer.

    abstract::Autologous bone marrow reinfusion rapidly repopulates severely damaged bone marrow thus shortening the period of myelosuppression following high-dose chemotherapy programs. This strategy has been successfully employed in several hematologic malignancies such as acute leukemia, Hodgkin's disease, non-Hodgkin's lymphoma...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:

    authors: Hortobagyi GN

    更新日期:1988-11-01 00:00:00

  • Autologous BMT in high risk patients with CALLA-positive ALL: possible efficacy of ex vivo marrow leukemia cell purging with monoclonal antibodies and complement.

    abstract::Autologous BMT (auto-BMT) has been conducted for 17 high-risk common ALL antigen (CALLA)-positive non-T cell type ALL patients. Ex vivo purging of leukemia cells from infused BM cells was performed using complement and three kinds of mouse monoclonal antibodies reactive to CALLA-positive leukemia cells: NL-1 (IgG2a), ...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:

    authors: Morishima Y,Miyamura K,Kojima S,Ueda R,Morishita Y,Sao H,Tanimoto M,Ohno R,Sobue R,Hirano M

    更新日期:1993-04-01 00:00:00

  • A risk-adapted approach to acute GVHD treatment: are we there yet?

    abstract::Acute GVHD (aGVHD) is an immunologic complication of allogeneic hematopoietic cell transplantation (HCT) that can range from mild to life-threatening. Models to predict patients at risk of poor outcomes have been developed using both clinical and laboratory data, and the time to test these models in clinical trials ha...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/bmt.2015.261

    authors: Holtan SG,MacMillan ML

    更新日期:2016-02-01 00:00:00

  • Phase I trial of histone deacetylase inhibitor panobinostat in addition to glucocorticoids for primary therapy of acute graft-versus-host disease.

    abstract::Glucocorticoids for primary therapy of acute GVHD have limited responses. A phase I/II trial tested 4 weeks of deacetylase inhibitor panobinostat started within 48 h of glucocorticoids (1 mg/kg/day prednisone or equivalent) as primary treatment for patients with either classic acute GVHD (n = 16) or acute GVHD overlap...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-018-0163-z

    authors: Perez L,Fernandez H,Horna P,Riches M,Locke F,Field T,Powers J,Sahakian E,Villagra A,Mishra A,Betts B,Kharfan-Dabaja M,Beato F,Ochoa-Bayona L,Pidala J,Anasetti C

    更新日期:2018-11-01 00:00:00

  • Chimerism monitoring following allogeneic hematopoietic stem cell transplantation.

    abstract::Information regarding the chimeric status of hematopoietic stem cell transplantation (HSCT) recipients is of great significance when comparing different conditioning and prophylactic therapies. In recent years, short tandem repeats/variable number tandem repeats (STRs/VNTRs) have emerged as the best tool for chimerism...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,随机对照试验

    doi:10.1038/sj.bmt.1705626

    authors: Talwar S,Khan F,Nityanand S,Agrawal S

    更新日期:2007-05-01 00:00:00

  • Thyroid function after autologous bone marrow transplantation.

    abstract::Thyroid function was prospectively analysed in 111 consecutive patients in relation to autologous bone marrow transplantation (ABMT). Median follow-up time was 12 (range 3-60) months. As part of the conditioning treatment 58 patients had received total body irradiation (TBI) as a single dose of 7.5 Gy (dose rate 0.15 ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Carlson K,Lönnerholm G,Smedmyr B,Oberg G,Simonsson B

    更新日期:1992-08-01 00:00:00

  • Predictors of short-term and long-term mortality in critically ill patients admitted to the intensive care unit following allogeneic stem cell transplantation.

    abstract::Historically, the mortality of patients admitted to the ICU after allogeneic stem cell transplantation (alloSCT) is high. Advancements in transplantation procedures, infectious monitoring and supportive care may have improved the outcome. This study aimed to determine short-term and long-term mortality after ICU admis...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-018-0277-3

    authors: van der Heiden PLJ,Arbous MS,van Beers EJ,van den Bergh WM,le Cessie S,Demandt AMP,Eefting M,Hess C,Kusadasi N,Marijt WAF,van Mook WNKA,Müller MCA,Tuinman PR,van Vliet M,van Westerloo DJ,Blijlevens NMA,HEMA-ICU Study Grou

    更新日期:2019-03-01 00:00:00